Comparative Analysis of Drug Policy Prices and National Procurement Systems in Universal Health Coverage

Erlisa Irawati Putri; Chairun Wiedyaningsih; Roshinta Andien Damayanti

doi:10.30595/jhepr.v4i1.352

Authors

Erlisa Irawati Putri Universitas Gadjah Mada
Chairun Wiedyaningsih Univresitas Gadjah Mada
Roshinta Andien Damayanti Universitas Gadjah Mada

DOI:

https://doi.org/10.30595/jhepr.v4i1.352

Keywords:

Asian Pharmaceutical Policy, Drug Prices, UHC, Pharmaceutical Procurement.

Abstract

Background: Access to affordable essential medicines is a key prerequisite for achieving Universal Health Coverage (UHC), particularly in developing countries facing fiscal pressures and pharmaceutical market inefficiencies. However, the effectiveness of medicine pricing policies varies significantly between countries, depending on regulatory design, procurement capacity, and political commitment to universal access.

Aims: This study aims to analyse and compare drug pricing policies and national procurement systems in five Asian countries—Indonesia, the Philippines, Thailand, Malaysia, and India—in the context of UHC.

Methods: This study employs a comparative policy analysis approach, utilising secondary data from national regulations, official government reports, and academic literature.

Results: Thailand has demonstrated the most effective model, combining HTA, compulsory licensing, and a centralized GPO system, which reduces drug prices by up to 90%. India optimises generic procurement through the Jan Aushadhi programme, while Malaysia combines external price references with tiered enforcement policies. In contrast, Indonesia and the Philippines still face challenges in price compliance and distribution efficiency, due to institutional fragmentation and weak oversight.

Conclusion: This study underscores the importance of integrating robust regulatory strategies, effective procurement mechanisms, and rigorous monitoring systems to ensure affordability and equitable access to medicines. Cross-country learning can strengthen national pharmaceutical reforms and support policy integration in the ASEAN region.

Keywords: Drug prices, UHC, pharmaceutical procurement, Asian pharmaceutical policy.

References

WHO. Everybody’s business -- strengthening health systems to improve health outcomes [Internet]. 2017 [cited 2025 July 9]. Available from: https://www.who.int/publications/i/item/everybody-s-business----strengthening-health-systems-to-improve-health-outcomes

Mounier-Jack S, Griffiths UK, Closser S, Burchett H, Marchal B. Measuring the health systems impact of disease control programmes: a critical reflection on the WHO building blocks framework. BMC Public Health [Internet]. 2014 Mar 25 [cited 2025 July 8];14(1):278. Available from: https://doi.org/10.1186/1471-2458-14-278

WHO. Measuring medicine prices, availability, affordability and price components, 2nd edition [Internet]. 2012 [cited 2025 July 9]. Available from: https://www.who.int/publications/i/item/WHO-PSM-PAR-2008.3

Pharmaceutical pricing policies and this guideline. In: WHO guideline on country pharmaceutical pricing policies [Internet] [Internet]. World Health Organization; 2020 [cited 2025 Dec 17]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK570140/

Tenni B, Moir HVJ, Townsend B, Kilic B, Farrell AM, Keegel T, et al. What is the impact of intellectual property rules on access to medicines? A systematic review. Glob Health [Internet]. 2022 Apr 15 [cited 2025 Dec 17];18(1):40. Available from: https://doi.org/10.1186/s12992-022-00826-4

Anggriani Y, Ramadaniati HU, Sarnianto P, Pontoan J, Suryawati S. The Impact of Pharmaceutical Policies on Medicine Procurement Pricing in Indonesia Under the Implementation of Indonesia’s Social Health Insurance System. Value Health Reg Issues [Internet]. 2020 May 1 [cited 2025 Dec 17];21:1–8. Available from: https://www.valuehealthregionalissues.com/article/S2212-1099(19)30084-6/fulltext

AG PN. DOH announces full implementation of drug price caps [Internet]. PTV News. 2022 [cited 2025 Dec 17]. Available from: https://ptvnews.ph/doh-announces-full-implementation-of-drug-price-caps/

WHO Guideline on Country Pharmaceutical Pricing Policies. 2nd ed. Geneva: World Health Organization; 2020. 1 p.

content [Internet]. [cited 2025 Dec 17]. Available from: https://iris.who.int/server/api/core/bitstreams/4c2e53e0-9845-43d4-933b-86c8c54d43fb/content

Pisani E, Olivier Kok M, Nugroho K. Indonesia’s road to universal health coverage: a political journey. Health Policy Plan [Internet]. 2016 Sept 6 [cited 2025 July 8];czw120. Available from: https://academic.oup.com/heapol/article-lookup/doi/10.1093/heapol/czw120

Warsito GM, Adisasmito W. Health inequality in wealth disparity: A narrative review of Indonesia’s health coverage protection against poverty. ASM Sci J. 2020;13(5).

LKPP. Evaluasi Awal Implementasi E-Katalog Obat. 2007;

Kementerian Kesehatan RI. Database Peraturan | JDIH BPK. 2015 [cited 2025 July 8]. Permenkes No. 98 Tahun 2015 tentang Harga Eceran Tertinggi (HET). Available from: http://peraturan.bpk.go.id/Details/116671/permenkes-no-98-tahun-2015

Kementerian Kesehatan RI. Database Peraturan | JDIH BPK. 2024 [cited 2025 July 9]. Perpres No. 59 Tahun 2024. Available from: http://peraturan.bpk.go.id/Details/285181/perpres-no-59-tahun-2024

Studocu [Internet]. [cited 2025 Dec 16]. Investigating Incentives in Indonesia’s Med Supply Chain (MED-401). Available from: https://www.studocu.vn/vn/document/international-university-vnu-hcm/logistic-and-supply-chain/pisani-et-al-indonesia-medicine-supply-chain/71360669

Anggriani Y, Sarnianto P, Aisyah S, Pontoan J. Trend Price Analysis of Drug Before and After the Implementation of E-catalogue at the Hospital. J Manaj DAN PELAYANAN Farm J Manag Pharm Pract [Internet]. 2019 Mar 29 [cited 2025 Dec 16];9(1):1–11. Available from: https://jurnal.ugm.ac.id/jmpf/article/view/44496

Anggriani Y, Ramadaniati HU, Sarnianto P, Pontoan J, Suryawati S. The Impact of Pharmaceutical Policies on Medicine Procurement Pricing in Indonesia Under the Implementation of Indonesia’s Social Health Insurance System. Value Health Reg Issues [Internet]. 2020 May 1 [cited 2025 Dec 16];21:1–8. Available from: https://www.sciencedirect.com/science/article/pii/S2212109919300846

BPOM. Laporan Tahunan 2023 | KLIK CPOB [Internet]. 2023 [cited 2025 July 9]. Available from: https://klikcpob.pom.go.id/laporan-tahunan/

Agustina R, Dartanto T, Sitompul R, Susiloretni KA, Suparmi, Achadi EL, et al. Universal health coverage in Indonesia: concept, progress, and challenges. The Lancet [Internet]. 2019 Jan 5 [cited 2025 July 9];393(10166):75–102. Available from: https://doi.org/10.1016/S0140-6736(18)31647-7

WHO. Indonesia in the 2023 Universal Health Coverage global monitoring report [Internet]. 2023 [cited 2025 July 8]. Available from: https://www.who.int/indonesia/news/detail/16-11-2023-indonesia-in-the-2023-universal-health-coverage-global-monitoring-report

Zahari TN, Hidayatno A, Komarudin. Sustainability Evaluation of Tobacco Excise Tax Policy to Finance Universal Health Coverage in Indonesia. In: 2021 IEEE International Conference on Industrial Engineering and Engineering Management (IEEM) [Internet]. 2021 [cited 2025 July 8]. p. 1636–40. Available from: https://ieeexplore.ieee.org/document/9672776

A Study Visit Report [Internet]. [cited 2025 Dec 16]. Available from: https://www.hitap.net/wp-content/uploads/2024/05/ReportPricing-study-visit_04.04.pdf

Sruamsiri R, Ross-Degnan D, Lu CY, Chaiyakunapruk N, Wagner AK. Policies and Programs to Facilitate Access to Targeted Cancer Therapies in Thailand. PLOS ONE [Internet]. 2015 Mar 23 [cited 2025 July 9];10(3):e0119945. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0119945

Central Procurement [Internet]. [cited 2025 Dec 16]. Available from: https://eng.nhso.go.th/assets/portals/1/files/Thailand_UHC/64-5_CentralProcurement_Book%28Eng%29.pdf?utm_source=chatgpt.com

Ministry of Public Health. Thailand National Essential Drug List. 2023;

Butani D, Faradiba ,Dian, Dabak ,Saudamini Vishwanath, Isaranuwatchai ,Wanrudee, Huang-Ku ,Evan, Pachanee ,Kumaree, et al. Expanding access to high-cost medicines under the Universal Health Coverage scheme in Thailand: review of current practices and recommendations. J Pharm Policy Pract [Internet]. 2023 Dec 31 [cited 2025 June 17];16(1):138. Available from: https://doi.org/10.1186/s40545-023-00643-z

Wibulpolprasert S, Chokevivat V, Oh C, Yamabhai I. Government use licenses in Thailand: The power of evidence, civil movement and political leadership. Glob Health [Internet]. 2011 Sept 12 [cited 2025 July 9];7(1):32. Available from: https://doi.org/10.1186/1744-8603-7-32

Kuanpoth J. Compulsory Licences: Law and Practice in Thailand. Compuls Licens [Internet]. 2014 July 25 [cited 2025 July 9];22:61–77. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122632/

Wibulpolprasert S, et al. The Thai Model of Drug Policy: Lessons for Developing Countries. The Lancet. 2018;

Department of Health [DOH]. Philippine National Drug Policy 2021-2030. Manila: Department of Health; 2021.

Lorenzo FM, et al. Drug Pricing Reforms in the Philippines: Achievements and Challenges. Health Policy Plan. 2022;37(3):345–59.

Philippine Food and Drug Administration [PFDA]. Annual Report on Drug Price Monitoring and Compliance. 2023;

Natividad VG. Botika ng Bayan Expansion Program Evaluation. Manila: University of the Philippines Press; 2021.

Nisperos GA, Ornos EDB. The Philippine Universal Health Care Law: A Differing View. Soc Med [Internet]. 2022;15(2):96–105. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85131781331&partnerID=40&md5=d501e1dd3a58db9e7147d0cf79841317

PhilGEPS. National Pharmaceutical Procurement Report 2022. Manila: Philippine Government Electronic Procurement System; 2022.

Ulep VG, et al. Compliance with Maximum Drug Retail Price in Philippine Retail Pharmacies. J Pharm Policy Pract. 2022;15(1):1–15.

Gouda HN, Hodge A, Bermejo R, Zeck W, Jimenez-Soto E. The impact of healthcare insurance on the utilisation of facility-based delivery for childbirth in the philippines. PLoS ONE [Internet]. 2016;11(12). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85001975371&doi=10.1371%2fjournal.pone.0167268&partnerID=40&md5=0e89c910be3026b039ec38040f81dbf4

Obermann K, Jowett MR, Alcantara MOO, Banzon EP, Bodart C. Social health insurance in a developing country: The case of the Philippines. Soc Sci Med [Internet]. 2006;62(12):3177–85. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-33646492018&doi=10.1016%2fj.socscimed.2005.11.047&partnerID=40&md5=80d50e28f69fc1fb86fafa2f7eda738d

Pepito VCF, Loreche AM, Legaspi RS, Guinaran RC, Capeding TPJZ, Ong MM, et al. Health workforce issues and recommended practices in the implementation of Universal Health Coverage in the Philippines: a qualitative study. Hum Resour Health [Internet]. 2025;23(1). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-105003170166&doi=10.1186%2fs12960-025-00988-3&partnerID=40&md5=4888bd043bfa0bc139ba03b748a57e3e

Obermann K, Jowett M, Kwon S. The role of national health insurance for achieving UHC in the Philippines: a mixed methods analysis. Glob Health Action [Internet]. 2018;11(1). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055620578&doi=10.1080%2f16549716.2018.1483638&partnerID=40&md5=22d003143504a0e456fe7aec290e998c

Hassali MA, et al. Medicine Pricing Policy in Malaysia. J Pharm Policy Pract. 2022;15(1):1–12.

Ismail N, et al. Evaluation of Malaysia’s Drug Price Control Measures: 2019-2022. Putrajaya: Ministry of Health Malaysia; 2022.

National Pharmaceutical Regulatory Agency [NPRA]. Medicine Price Control Monitoring Report 2023. 2023;

Ministry of Health Malaysia [MOH]. National Medicines Policy 2021-2025: Ensuring Affordable and Quality Medicines. Putrajaya: Pharmaceutical Services Programme; 2021.

Ministry of Health Malaysia [MOH]. Annual Report on Pharmaceutical Procurement and Pricing 2023. Putrajaya: Pharmaceutical Services Division; 2023.

Lim KM, Teh PC, Lee SWH. Supply Chain Challenges in Malaysia’s Pharmaceutical Sector: A Qualitative Analysis. Asian J Pharm. 2021;15(3):45–58.

Ali NH, Mohamed Shah N, Hassali MA. Compliance with Maximum Medicine Price Regulation in Malaysian Community Pharmacies: A Nationwide Survey. J Pharm Health Serv Res. 2023;14(2):123–35.

Chaudhuri S. India’s Compulsory Licensing Experience. J Generic Med. 2022;18(3):123–35.

National Pharmaceutical Pricing Authority [NPPA]. Annual Report on Drug Price Control. 2023;

Jindal AK. Universal health coverage: the way forward. Indian J Public Health [Internet]. 2014;58(3):161–7. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84907773449&doi=10.4103%2f0019-557X.138622&partnerID=40&md5=5c73428941cfe0b5b4da2c78c1ffee79

Srinivas KR, et al. Comparative Analysis of Drug Pricing Policies in Southeast Asia. Health Policy Technol. 2022;11(2):100612.

Balarajan Y, Selvaraj S, Subramanian S. Health care and equity in India. The Lancet [Internet]. 2011;377(9764):505–15. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-79551681501&doi=10.1016%2fS0140-6736%2810%2961894-6&partnerID=40&md5=2a996577a4654123a03177d1e4727112

Achungura G, Raza A, Katre V, Anand JS, Ravishankar N, Kelkar R. Data Integration of Health Financing Systems as a Critical Enabler for Objective-Oriented Health System Reform: A Scoping Review from India. Health Syst Reform [Internet]. 2024;10(3). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85209476816&doi=10.1080%2f23288604.2024.2401190&partnerID=40&md5=c1e884eeebbc67be80f989814dc17bc1

Bureau of Pharma PSUs of India. Jan Aushadhi Scheme: 8 Years Progress Report. BPPI; 2023.

Goyal A, et al. Regional Disparities in Medicine Pricing in India. Health Policy Plan. 2023;

Reddy KS, Patel V, Jha P, Paul VK, Kumar AKS, Dandona L. Towards achievement of universal health care in India by 2020: A call to action. The Lancet [Internet]. 2011;377(9767):760–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-79952105109&doi=10.1016%2fS0140-6736%2810%2961960-5&partnerID=40&md5=719a20ae62b3f35c9726090070e6aed3

Federation of Indian Chambers of Commerce & Industry [FICCI]. Indian Pharmaceutical Industry: Challenges and Opportunities. FICCI; 2023.

Maqbool M, Dar MA, Rasool S, Gani I, Geer MI. Universal health coverage policy and practice framework in india: A review. Res J Pharm Technol [Internet]. 2019;12(8):4045–51. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85074175530&doi=10.5958%2f0974-360X.2019.00697.8&partnerID=40&md5=d572e100e2aa2215cebe1715d14aeea0

Gera R, Narwal R, Jain M, Taneja G, Gupta S. Sustainable development goals: Leveraging the global agenda for driving health policy reforms and achieving universal health coverage in India. Indian J Community Med [Internet]. 2018;43(4):255–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85059486502&doi=10.4103%2fijcm.IJCM_41_18&partnerID=40&md5=01f6ea378606d37f7de5a6c536372fb3

Selvaraj S, et al. Evaluating India’s Jan Aushadhi Scheme. BMJ Glob Health. 2022;

Bureau of Pharma PSUs of India [BPPI]. Annual Report 2022-23: Pradhan Mantri Bhartiya Janaushadhi Pariyojana. New Delhi: BPPI; 2023.

Kanavos P, et al. Pricing Policies for Pharmaceuticals in Thailand. Health Policy. 2020;

Banerjee S. Determinants of rural-urban differential in healthcare utilization among the elderly population in India. BMC Public Health [Internet]. 2021;21(1). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85106259182&doi=10.1186%2fs12889-021-10773-1&partnerID=40&md5=98fbc6fa3b6089a2e9ef4547d915a72d

Wouters OJ, Denolle C, Wei J, Papanicolas I. Prices and Affordability of Essential Medicines in 72 Low-, Middle-, and High-Income Markets. JAMA Health Forum [Internet]. 2025 Aug 15 [cited 2025 Dec 16];6(8):e252043. Available from: https://jamanetwork.com/journals/jama-health-forum/fullarticle/2837522

Pablos-Méndez A, Evans TG. Universal Health Coverage (UHC): From Global Consensus to National Action. In: Sustainable Development Goals Series [Internet]. 2023. p. 279–83. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85194589175&doi=10.1007%2f978-3-031-33851-9_42&partnerID=40&md5=66d2806bce1e1a915346a7d6655602c8.